ARA-290 in Renal Ischemia-Reperfusion Research: Renal Function, Inflammation, and Tissue Findings

ARA-290 Research in Renal Ischemia-Reperfusion Models

Experimental Renal Ischemia and Reperfusion

Renal ischemia-reperfusion involves a temporary interruption of blood flow followed by restoration. This sequence produces measurable changes in kidney function, and tissue injury. Researchers use the model to examine how the kidney responds to the period of ischemia and subsequent reperfusion.

Published ARA-290 Renal Studies

A porcine study used unilateral renal ischemia and evaluated the ischemic kidney over seven days after reperfusion. Its primary renal endpoint was glomerular filtration rate. The study also measured urine flow, plasma creatinine, urea, inflammatory gene expression, renal morphology, α-SMA, TGF-β, and urinary NOx.

A later rat study examined ARA-290 at different post-reperfusion time points and evaluated renal function, IL-6 and TNF-α expression, granulocyte infiltration, renal morphology, KIM-1, and α-SMA.

Other renal ischemia-reperfusion experiments used pHBSP or HBSP. The pHBSP study examined renal and tubular dysfunction after 30 minutes of ischemia and 48 hours of reperfusion. The HBSP study examined renal injury after ischemia and a longer two-week reperfusion period, including experiments involving cyclosporine A.

Renal Function Findings

Glomerular Filtration and Urine Measurements

The porcine ARA-290 study found a significant increase in glomerular filtration rate during the seven-day observation period. The investigators calculated GFR for the ischemic kidney using urinary and plasma creatinine measurements because the contralateral kidney could compensate for loss of function and make plasma creatinine alone unsuitable for assessing the ischemic kidney.

Urine flow did not differ between the ARA-290 and vehicle groups in that study. The reported GFR difference therefore occurred without a corresponding difference in measured urine flow.

Creatinine and Urea Measurements

The porcine study found no difference in plasma creatinine between ARA-290 and vehicle groups. Plasma urea also did not differ between groups.

The rat ARA-290 study reported a significant reduction in serum creatinine at three days after reperfusion when the early experimental condition was used. Serum urea showed the same direction of change, but the difference was not statistically significant. The later and repeated experimental conditions did not significantly change serum creatinine.

The earlier pHBSP study also reported lower serum creatinine and serum urea after renal ischemia-reperfusion compared with untreated ischemia-reperfusion animals. That experiment additionally measured estimated creatinine clearance and fractional sodium excretion.

Inflammatory Responses After Renal Ischemia-Reperfusion

Cytokine and Chemokine Findings

In the porcine study, renal ischemia increased IL-6 and MCP-1 mRNA expression before reperfusion. At 15 minutes after reperfusion, ARA-290 produced a trend toward lower IL-6 and MCP-1 expression. But the differences did not reach statistical significance. TNF-α mRNA expression was not changed by ARA-290 at this time point. At seven days, the study found no differences in inflammatory markers.

In the rat study, early ARA-290 treatment significantly reduced renal IL-6 mRNA expression at three days after reperfusion. TNF-α expression also showed a downward trend, but the change was not statistically significant. Late and repetitive treatment did not significantly change IL-6 or TNF-α expression.

Inflammatory Cell Findings

The rat ARA-290 study assessed granulocyte infiltration using HIS-48 staining. Early experimental treatment produced a trend toward lower HIS-48 expression in cortical tissue. The later and repeated experimental conditions did not significantly change the measurement.

The separate HBSP renal ischemia-reperfusion study also examined inflammatory-cell infiltration. Myeloperoxidase-positive cells increased in the ischemia-reperfusion groups and were reduced by HBSP in the experimental groups examined.

Renal Tissue Findings

Renal Morphology and Tubular Injury

The rat ARA-290 study found marked tubular dilation, cell death and cellular debris in control kidneys three days after reperfusion. The early experimental condition showed substantially less structural damage. The later and repeated conditions produced smaller reductions in the observed renal damage.

The porcine study used periodic acid-Schiff staining to assess renal morphology seven days after reperfusion. Control ischemic kidneys showed interstitial fibrotic changes, while these morphological changes were reduced in the ARA-290 group.

The HBSP study assessed tubulointerstitial damage by histological examination. Ischemia-reperfusion produced tubular dilation, epithelial-cell vacuolation, interstitial expansion, and cellular material within tubular lumens. HBSP reduced the reported tubulointerstitial injury scores in the experimental groups.

KIM-1 and Fibrotic Findings

The rat ARA-290 study reported reduced KIM-1 mRNA and cortical KIM-1 protein expression with early treatment. Later and repeated treatment did not significantly change KIM-1 expression.

In the porcine study, ARA-290 reduced interstitial α-SMA staining and TGF-β mRNA expression at seven days after reperfusion. α-SMA mRNA showed a similar trend. The study also reported reduced interstitial fibrosis.

The rat study found no significant difference in α-SMA mRNA or cortical α-SMA protein expression between the experimental groups.

The HBSP study reported reduced tubulointerstitial fibrosis and collagen deposition after renal ischemia-reperfusion.

Nitric Oxide-Related Findings

The porcine ARA-290 study measured total nitrite and nitrate, reported as NOx, in plasma and urine. Plasma NOx did not differ between groups. Urinary NOx excretion was significantly higher in the ARA-290 group at 24 hours after reperfusion. NOx clearance was also significantly higher at that time point.

The study used urinary NOx and NOx clearance as measurements related to nitric oxide synthase activity. The authors noted that the measurements could not distinguish between NOx associated with endothelial nitric oxide synthase and inducible nitric oxide synthase.

Experimental Timing and Differences Between Studies

The studies differed in species, experimental timing, reperfusion periods and study design. The rat ARA-290 study compared early, late, and repeated experimental conditions, while the porcine study followed the ischemic kidney for seven days. The pHBSP study used 48 hours of reperfusion, whereas the HBSP study assessed outcomes after two weeks.

These differences in experimental design and observation periods limit direct comparison between the studies.

Interpreting the Renal Research Evidence

The renal findings varied with the animal model and experimental timing. Differences were reported between the porcine and rat studies and some effects observed under early conditions were not reproduced at later time points.

The evidence remains preclinical. The studies used different species, ischemia-reperfusion designs, observation periods and outcome measures. Some experiments also used the related designations pHBSP or HBSP, which further limits direct comparison across the literature.

These findings do not establish a clinical effect in humans. They describe outcomes observed in experimental renal ischemia-reperfusion models only.

FAQs

References

1. van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Jespersen B, Ottens PJ, Ploeg RJ, Leuvenink HG. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med. 2013 Jan 9;11:9. PubMed ↗
2. van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Ottens PJ, Ploeg RJ, Leuvenink HG. Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury. J Transl Med. 2013 Nov 13;11:286. PubMed ↗
3. Patel NS, Kerr-Peterson HL, Brines M, Collino M, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiemermann C. Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury. Mol Med. 2012 May 9;18(1):719-27. PubMed ↗
4. Wu Y, Zhang J, Liu F, Yang C, Zhang Y, Liu A, Shi L, Wu Y, Zhu T, Nicholson ML, Fan Y, Yang B. Protective effects of HBSP on ischemia reperfusion and cyclosporine a induced renal injury. Clin Dev Immunol. 2013;2013:758159. PubMed ↗